The convertible loan notes agreement was part of the investment made by these investors in May 2012. On November 4, 2013 an extraordinary shareholders' meeting will be held to approve a share capital increase in the form of a rights offering which could result in cash proceeds of up to CHF 17.6 million. CHF 9 million of the proposed capital increase is already firmly committed by Abingworth, venBio, Amgen and Aisling. These shareholders hold collectively more than 50% of the outstanding share capital and have committed to vote in favor of the ordinary capital increase as well as the increase in conditional and authorized capital as proposed by the Board of Directors. The additional cash proceeds will ensure that Cytos remains well capitalized to further advance the development of its lead program CYT003. On Oc to ber 23, 2013 the company conducted an R&D update for inves to rs and analysts focused on its lead program CYT003. The presentations can be accessed as a webcast on the company's home page.